September 1, 2021

National ALS Registry Meeting 2021: Featuring Dr. Stephen Goutman

The National ALS Registry, managed by the Center for Disease Control (CDC) is one of the most important weapons in the fight against Amyotrophic Lateral Sclerosis (ALS).  At the Annual Surveillance Meeting, Pranger ALS Clinic Director Dr. Stephen Goutman presented an update of important findings funded by the CDC.

The Center for Disease Control (CDC) has been a key longtime ally in our fight against Amyotrophic Lateral Sclerosis (ALS), both by funding research initiatives as the ALS Center of Excellence and in the management of the National ALS Registry.

Dr. Stephen Goutman

Each year, the National ALS Registry Annual Surveillance meeting is held to update persons who work on ALS or are affected by the disease on the the progress of the National ALS Registry, the registry data itself and its implications.  During the 2021 event, Pranger ALS Clinic Director Dr. Stephen Goutman was a featured speaker.  He shared about our important CDC-funded initiative that is looking at "Key Metabolomic Signatures Linking ALS to Persistent Organic Pollutants.  

5 key takeaways from his presentation:

1.   Metabolite: A substance made or used when the body breaks down food, drugs or chemicals, or its own tissue (for example, fat or muscle tissue).

2.   We believe that Persistent organic pollutants (POPs), & other environmental exposure types, will lead to unique metabolite signatures detected in both plasma and central nervous system tissue in ALS subjects. Identifying these signatures will:

3.   Both samples obtained once, and those looked at over time, suggest an association of metabolites and progression of disability in patients with amyotrophic lateral sclerosis (ALS).

4.   Exposure models show a statistically significant high occupational risk factor for ALS in individuals exposed to metals.  It was also increased in those exposed to particulate matter, volatile organic compounds (chemicals found in paints, pharmaceuticals and refrigerants) and combustion/diesel exhaust.

5.   Our next steps in this work include the following:

    • Continue to identify unique metabolomic signatures and refine data.
    • Explore how to account for other ALS metabolomics dysregulation in conjunction with that associated with persistent organic pollutants.
    • Determine whether metabolomic signatures in ALS subject plasma are present in post-mortem brain and spinal cord tissue and correlate with exposures.

 What is the National ALS Registry?

courtesy of the ALS National Registry